Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Food Allergenic Extract [EPC]
Chenopodium Ambrosioides is a non-standardized allergenic extract used primarily in the diagnosis and treatment of specific plant-based allergies. It belongs to the class of food and plant allergenic extracts.
Name
Chenopodium Ambrosioides
Raw Name
CHENOPODIUM AMBROSIOIDES
Category
Non-Standardized Food Allergenic Extract [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Chenopodium Ambrosioides
Chenopodium Ambrosioides is a non-standardized allergenic extract used primarily in the diagnosis and treatment of specific plant-based allergies. It belongs to the class of food and plant allergenic extracts.
Detailed information about Chenopodium Ambrosioides
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Chenopodium Ambrosioides.
Chenopodium Ambrosioides, taxonomically known as Dysphania ambrosioides and colloquially referred to as Epazote, Wormseed, or Mexican Tea, is a perennial herb native to Central America, South America, and southern Mexico. In the context of modern clinical pharmacology, Chenopodium Ambrosioides is utilized as a Non-Standardized Plant Allergenic Extract [EPC]. This pharmaceutical preparation is derived from the proteins and antigenic components of the plant, intended for use by medical professionals—specifically allergists and immunologists—to diagnose or treat hypersensitivity reactions.
Chenopodium Ambrosioides belongs to a class of drugs called allergenic extracts. These are biological substances used for the diagnosis of IgE-mediated (Type I) allergies and for allergen immunotherapy (AIT). According to the FDA regulatory framework, these extracts are 'non-standardized,' meaning that while they are manufactured under strict Current Good Manufacturing Practices (cGMP), they do not have a federally mandated potency unit (like an International Unit) defined by a specific bioassay. Instead, they are typically measured in Protein Nitrogen Units (PNU) or weight-to-volume (w/v) ratios. The FDA has a long history of licensing these extracts under the Public Health Service Act, ensuring that they meet safety and purity standards for clinical application.
Historically, Chenopodium Ambrosioides was used in traditional medicine as an anthelmintic (a medication used to expel parasitic worms), primarily due to its high concentration of ascaridole. However, due to the narrow therapeutic index and potential for severe neurotoxicity and nephrotoxicity, its use as an oral anthelmintic has been largely superseded by safer synthetic alternatives like albendazole or mebendazole in Western medicine. Today, its primary clinical relevance in the United States and Europe is as an allergen used in skin testing and desensitization protocols for patients who exhibit allergic rhinitis, asthma, or contact dermatitis triggered by this specific botanical species.
The mechanism of action for Chenopodium Ambrosioides allergenic extract depends entirely on its clinical application: diagnostic or therapeutic.
When used for diagnostic purposes (such as a Skin Prick Test or Intradermal Test), the extract is introduced into the epidermis or dermis. If the patient is sensitized to Chenopodium Ambrosioides, they possess specific Immunoglobulin E (IgE) antibodies bound to the surface of mast cells in their skin. The allergenic proteins in the extract cross-link these IgE molecules, triggering mast cell degranulation. This release of inflammatory mediators—primarily histamine, leukotrienes, and prostaglandins—leads to the 'wheal and flare' reaction (a raised bump and surrounding redness). This reaction is a localized Type I hypersensitivity response, allowing the clinician to confirm the presence of specific sensitization.
When used in Allergen Immunotherapy (AIT), the extract is administered in gradually increasing doses (the 'build-up phase') until a maintenance dose is reached. At the molecular level, this process is designed to induce 'immune tolerance.' The repeated exposure to the allergen shifts the immune response from a Th2-dominated profile (which promotes IgE production and allergy) to a Th1-dominated or T-regulatory (Treg) cell response. This leads to the production of 'blocking antibodies,' specifically IgG4, which compete with IgE for allergen binding, thereby preventing the allergic cascade upon subsequent natural exposure to the plant or its pollen.
Traditional pharmacokinetic parameters (Absorption, Distribution, Metabolism, and Elimination) are characterized differently for allergenic extracts compared to small-molecule drugs, as these extracts are complex mixtures of proteins and glycoproteins.
Chenopodium Ambrosioides allergenic extract is indicated for the following:
> Important: Only your healthcare provider can determine if Chenopodium Ambrosioides is right for your specific condition.
Dosage for Chenopodium Ambrosioides allergenic extract is highly individualized and must be determined by a specialist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.
Chenopodium Ambrosioides allergenic extract can be used in children, but extreme caution is required.
No specific dosage adjustments are required for patients with renal impairment, as the extract is not cleared primarily by the kidneys. However, the patient's overall health and ability to tolerate a systemic reaction must be considered.
No dosage adjustments are required for hepatic impairment. The metabolic pathway of allergenic proteins does not involve hepatic CYP450 enzymes.
Geriatric patients may be at higher risk for complications if a systemic reaction occurs, particularly if they have underlying cardiovascular disease. Dose escalation should be performed with extra caution, and the maintenance dose may be kept lower than in younger adults.
Chenopodium Ambrosioides allergenic extract is NOT for self-administration. It must be administered by a healthcare professional in a clinical setting equipped to treat anaphylaxis.
In immunotherapy, consistency is vital. If a dose is missed:
An 'overdose' in the context of allergenic extracts refers to the administration of a dose that exceeds the patient's current tolerance level, potentially leading to a severe systemic reaction.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Most patients receiving Chenopodium Ambrosioides extracts will experience some form of local reaction. These are generally not dangerous but indicate the immune system's response to the allergen.
> Warning: Stop taking Chenopodium Ambrosioides and call your doctor immediately if you experience any of these.
There are no known long-term 'toxic' side effects of Chenopodium Ambrosioides allergenic extracts when used as directed. The primary long-term effect is the intended modification of the immune system. However, patients should be monitored over the years for any changes in their baseline allergic status or the development of new sensitivities.
While Chenopodium Ambrosioides extracts may not have a specific individual black box warning, the entire class of allergenic extracts carries a general warning regarding the risk of severe systemic reactions.
FDA Class Warning Summary: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at increased risk. Extracts should only be administered by healthcare providers prepared to manage anaphylaxis. Patients should be observed for at least 30 minutes post-injection.
Report any unusual symptoms to your healthcare provider.
Chenopodium Ambrosioides allergenic extract is a potent biological product. Safety depends on accurate dosing, proper administration technique, and the patient’s current health status. It is crucial that patients disclose their full medical history, including any history of heart disease, lung disease, or use of medications like beta-blockers.
No specific FDA black box warning exists solely for Chenopodium Ambrosioides; however, it is subject to the standard warnings for all non-standardized allergenic extracts. These warnings emphasize that immunotherapy should only be performed in facilities where emergency equipment and trained personnel are available to treat anaphylactic shock.
In most cases, Chenopodium Ambrosioides does not affect the ability to drive. However, if a patient experiences a large local reaction or mild systemic symptoms (like dizziness or fatigue), they should wait until these symptoms resolve before operating a vehicle or heavy machinery.
Alcohol consumption should be avoided on the day of an immunotherapy injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially increase the risk or severity of a systemic reaction.
Immunotherapy is typically continued for 3 to 5 years. Stopping the treatment early may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the clinical benefits will gradually diminish over time if the course is not completed.
> Important: Discuss all your medical conditions with your healthcare provider before starting Chenopodium Ambrosioides.
For each major interaction, explain:
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Chenopodium Ambrosioides.
FDA Pregnancy Category C (Equivalent): There are no adequate and well-controlled studies of Chenopodium Ambrosioides extract in pregnant women.
It is not known whether the components of Chenopodium Ambrosioides allergenic extract are excreted in human milk. However, because the extract consists of proteins that are likely digested in the infant's gut, the risk to a nursing infant is considered very low. The decision to continue immunotherapy while breastfeeding should be a risk-benefit discussion between the patient and their doctor.
No dosage adjustment is required for patients with renal disease. However, if the patient has end-stage renal disease (ESRD), their overall physiological reserve may be diminished, necessitating a more cautious approach to dose escalation.
No dosage adjustment is required for patients with hepatic impairment. The liver does not play a primary role in the clearance of these allergenic proteins.
> Important: Special populations require individualized medical assessment.
Chenopodium Ambrosioides extract works by interacting with the Type I hypersensitivity pathway. In sensitized individuals, the extract's proteins bind to specific IgE antibodies on mast cells and basophils. For diagnosis, this triggers localized mediator release. For therapy, the repeated, controlled exposure induces T-regulatory cells, which secrete IL-10 and TGF-beta. These cytokines suppress the Th2 allergic response and induce B-cells to switch from producing IgE to producing IgG4, a non-inflammatory 'blocking' antibody.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Percutaneous) |
| Protein Binding | Minimal (processed by APCs) |
| Half-life | Variable (Proteins degraded in hours) |
| Tmax | 30–60 minutes (systemic absorption) |
| Metabolism | Local Proteolysis |
| Excretion | Cellular turnover/Metabolic pathways |
Chenopodium Ambrosioides is classified as a Non-Standardized Plant Allergenic Extract. It is related to other weed and herb extracts such as Ragweed (Ambrosia), Mugwort (Artemisia), and Lamb's Quarters (Chenopodium album).
Medications containing this ingredient
Common questions about Chenopodium Ambrosioides
Chenopodium Ambrosioides allergenic extract is primarily used by allergists to diagnose and treat specific allergies to the Epazote plant or its pollen. In diagnostic testing, it is applied to the skin to see if a 'wheal and flare' reaction occurs, indicating a sensitivity. In treatment, known as immunotherapy or 'allergy shots,' small, increasing amounts of the extract are injected over time to help the immune system become less sensitive to the plant. This can significantly reduce symptoms of allergic rhinitis (hay fever) and asthma. It is not used as a general medication for other conditions in modern clinical practice.
The most frequent side effects are localized to the site of the injection or skin test. Patients often experience redness, itching, and swelling at the site where the extract was introduced. These reactions are usually mild and resolve within a few hours to a day. Some patients may also experience a temporary increase in their typical allergy symptoms, such as sneezing or watery eyes. While rare, more significant swelling (large local reactions) can occur. Because of the risk of a severe systemic reaction, all patients are monitored for 30 minutes after administration.
It is strongly recommended to avoid alcohol on the days you receive an immunotherapy injection of Chenopodium Ambrosioides. Alcohol causes your blood vessels to dilate (expand), which can speed up the absorption of the allergen into your bloodstream. This increased absorption rate can raise the risk of a systemic allergic reaction or make a reaction more severe if it occurs. Additionally, alcohol can mask early symptoms of an allergic reaction, such as feeling flushed or dizzy. Always wait at least 24 hours after an injection before consuming alcohol.
The safety of Chenopodium Ambrosioides during pregnancy is complex and requires a discussion with your doctor. Generally, healthcare providers will not start a new course of allergy shots during pregnancy because the risk of a severe reaction (anaphylaxis) could harm the baby by reducing oxygen supply. However, if a woman is already on a stable 'maintenance' dose and becomes pregnant, the treatment is often continued because the risk of a reaction is much lower at that stage. The dose is typically not increased during the pregnancy. Your allergist will help you weigh the risks of the treatment against the benefits of controlling your allergies.
When used for diagnostic skin testing, the extract works almost immediately, with results visible within 15 to 20 minutes. However, when used as a treatment (immunotherapy), it is a slow process that requires patience. Most patients do not notice a significant reduction in their allergy symptoms until they have reached their 'maintenance dose,' which usually takes 3 to 6 months of weekly injections. Full clinical benefit is typically seen after 12 months of treatment. A complete course of therapy usually lasts 3 to 5 years to ensure long-lasting immune tolerance.
Yes, you can stop taking Chenopodium Ambrosioides immunotherapy injections at any time without experiencing physical withdrawal symptoms. Unlike some medications that require tapering (like steroids), allergenic extracts do not cause a 'rebound' effect. However, if you stop the treatment before the recommended 3 to 5-year course is complete, your allergy symptoms are likely to eventually return to their original severity. If you miss several doses, you should not simply resume at your previous dose; your doctor will need to adjust the dose downward for safety.
If you miss a scheduled immunotherapy injection, you should contact your allergist's office as soon as possible to reschedule. Do not attempt to 'double up' on your next dose. The safety of the next injection depends on how much time has passed since your last one. If only a few days have passed, you may be able to continue with your scheduled dose. If several weeks have passed, your doctor will likely need to reduce the dose to prevent a reaction. Consistency is the most important factor in making the treatment both safe and effective.
There is no evidence to suggest that Chenopodium Ambrosioides allergenic extract causes weight gain. The extract consists of a very small amount of protein and glycerin, which has no significant caloric value or metabolic effect on body weight. If you experience weight changes while undergoing immunotherapy, it is likely due to other factors, such as changes in lifestyle, diet, or other medications (like oral corticosteroids) you may be taking to manage your allergy symptoms. Always discuss unexpected weight changes with your primary care physician.
Chenopodium Ambrosioides can be taken with many medications, but there are critical exceptions. You must tell your doctor if you are taking beta-blockers, as these can make it dangerous to treat a severe allergic reaction. Antihistamines must be stopped several days before skin testing because they will block the test results. Other medications like ACE inhibitors or MAOIs may also require special consideration. Most standard medications for other conditions, such as cholesterol or thyroid drugs, do not interact with allergenic extracts.
The concept of 'generic' is slightly different for allergenic extracts than for standard pills. Chenopodium Ambrosioides is a biological product produced by several different specialized laboratories. While different companies may produce the extract, they are not considered 'generics' of one another in the way that generic ibuprofen is to Advil. Each manufacturer's extract may have slight variations in protein composition. Therefore, allergists generally prefer to stick with the same manufacturer's extract throughout a patient's treatment course to ensure consistent dosing and safety.